Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | +3.47% | +7.19% | -45.51% |
04-11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
04-11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
Sales 2024 * | 28.05M 2.24B | Sales 2025 * | 72.09M 5.76B | Capitalization | 42M 3.35B |
---|---|---|---|---|---|
Net income 2024 * | -1M -79.83M | Net income 2025 * | 39M 3.11B | EV / Sales 2024 * | 1.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.58 x |
P/E ratio 2024 * |
246
x | P/E ratio 2025 * |
0.92
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.89% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | +3.47% | ||
1 week | +7.19% | ||
Current month | +3.47% | ||
1 month | -26.46% | ||
3 months | -39.93% | ||
6 months | -42.86% | ||
Current year | -45.51% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | 10-31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | 02-13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 31/10/20 |
James Manuso
BRD | Director/Board Member | 75 | 31/12/18 |
Susan Benton
BRD | Director/Board Member | 59 | 31/10/20 |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 1.64 | +3.47% | 44,231 |
30/04/24 | 1.585 | -3.94% | 37,052 |
29/04/24 | 1.65 | +2.48% | 82,473 |
26/04/24 | 1.61 | +4.89% | 113,959 |
25/04/24 | 1.535 | +0.33% | 110,754 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.51% | 39.33M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- OCUP Stock